Xian-janssen Pharmaceutical Ltd.
Clinical trials sponsored by Xian-janssen Pharmaceutical Ltd., explained in plain language.
Pharmaceutical company, a joint venture of Johnson & Johnson in China.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New study tests biologic drug guselkumab for ulcerative colitis in chinese patients
Disease control Recruiting nowThis study follows 200 Chinese patients with moderate-to-severe ulcerative colitis who have never taken biologic drugs. They will receive guselkumab as part of their normal care. Researchers will measure changes in symptoms and quality of life over 48 weeks to see how well the dr…
Sponsor: Xian-Janssen Pharmaceutical Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for Crohn's patients: study tests guselkumab after ustekinumab fails
Disease control Recruiting nowThis study tests whether guselkumab can help people with Crohn's disease whose current treatment (ustekinumab) has stopped working. Crohn's disease causes severe gut inflammation. About 78 Chinese adults with active Crohn's will receive guselkumab and be followed for 48 weeks to …
Phase: PHASE4 • Sponsor: Xian-Janssen Pharmaceutical Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC